Experimental combo targets tough lung cancer
NCT ID NCT02513563
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested whether adding an experimental drug called AZD1775 to standard chemotherapy (carboplatin and paclitaxel) could help people with advanced squamous cell lung cancer. The study enrolled 42 participants and measured how long they lived without their cancer getting worse. The goal was to see if the combination is safe and effective enough to pursue in larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD1775 (also called MK1775) combined with carboplatin and paclitaxel chemotherapy
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced squamous cell lung cancer who have few alternatives.
- What could go wrong
- This is a small, early-phase trial with only 42 participants, so results may not apply to everyone. The drug combination may cause significant side effects and may not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Can a new PET tracer light up hidden cancers?
- Fellow veterans may hold the key to earlier lung cancer detection